Cervical Cancer: Avastin Dosing and Usage

Persistent, recurrent, or metastatic cervical cancer (CC)
Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Approved Avastin dose in CC with paclitaxel/cisplatin or paclitaxel/topotecan

In persistent, recurrent, or metastatic CC, Avastin is administered as a solution for intravenous (IV) infusion at the following dose and schedule[1]:

Tumor type Chemotherapy Avastin dose Avastin schedule
CC* Cisplatin/paclitaxel 15 mg/kg IV Every 3 weeks
Topotecan/paclitaxel 15 mg/kg IV Every 3 weeks

*15 mg/kg IV dose evaluated in CC in combination with either cisplatin/paclitaxel or topotecan/paclitaxel.

  • 15 mg/kg solution for IV infusion every 3 weeks is the only dose of Avastin demonstrated to significantly increase OS in women with CC[1]

Important treatment considerations—Women of childbearing potential

  • Avastin increases the risk of ovarian failure and may impair fertility. Inform females of reproductive potential of the risk of ovarian failure prior to the first dose of Avastin
  • Long-term effects of Avastin exposure on fertility are unknown
  • Patients should also use effective contraception during treatment and for 6 months following the last dose of Avastin
  • Nursing mothers should not breastfeed during treatment and for 6 months following their last dose of treatment

Duration of Avastin in persistent, recurrent, or metastatic CC

Avastin Prescribing Information includes duration of Avastin treatment

FDA-approved Prescribing Information for the duration of Avastin treatment

Patients should continue treatment until disease progression or unacceptable toxicity.[1]

Important treatment considerations—dose modifications

No dose reductions for Avastin are recommended.

Dose Modifications for Adverse Reactions

Adverse reaction Severity  Dosage modification
Gastrointestinal perforation and fistulae
  • Gastrointestinal perforation, any grade
  • Tracheoesophageal fistula, any grade
  • Fistula, Grade 4
  • Fistula formation involving any internal organ
Discontinue Avastin
Wound healing complications Any Withhold Avastin until adequate wound healing. The safety of resumption of Avastin after resolution of wound healing complications has not been established.
Necrotizing fasciitis Discontinue Avastin
Hemorrhage Grade 3 or 4 Discontinue Avastin
Recent history of hemoptysis of ½ teaspoon (2.5 mL) or more Withhold Avastin
Thromboembolic events
  • Arterial thromboembolism, severe
  • Venous thromboembolism, Grade 4
Discontinue Avastin
  • Hypertensive crisis
  • Hypertensive encephalopathy
Discontinue Avastin
Hypertension, severe Withhold Avastin if not controlled with medical management; resume once controlled
Posterior reversible encephalopathy syndrome (PRES) Any Discontinue Avastin
Renal toxicity and proteinuria Nephrotic syndrome Discontinue Avastin
Proteinuria greater than or equal to 2 grams per 24 hours in absence of nephrotic syndrome
Withhold Avastin until proteinuria less than 2 grams per 24 hours
Infusion-related reaction Severe Discontinue Avastin
Clinically significant Interrupt infusion; resume at a decreased rate of infusion after symptoms resolve
Mild, clinically insignificant Decrease infusion rate
Congestive heart failure Any Discontinue Avastin

Inclusion of bevacizumab in National Comprehensive Cancer Network® (NCCN®) recommendations

National Comprehensive Cancer Network (NCCN) recommendations:

Bevacizumab is included as part of first-line treatment options for treating recurrent or metastatic CC[17]

Category 1
  • Cisplatin/paclitaxel + bevacizumab
  • Topotecan/paclitaxel + bevacizumab

The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.